e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
         
Colorado   000-30489   84-1097796
         
(State or other jurisdiction   (Commission File Number)   (IRS Employer Identification No.)
of incorporation)        
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 2.02 Results of Operations and Financial Condition
     On May 15, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.” The press release is attached as Exhibit 99.1 hereto.
Item 7.01 Regulation FD Disclosure
     On May 15, 2006, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.” The press release is attached as Exhibit 99.1 hereto.
Item 9.01 Exhibits
     99.1 Press release, dated May 15, 2006, entitled “Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.”
SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 16, 2006
         
  LIFELINE THERAPEUTICS, INC.
 		  
  By:   /s/ Stephen K. Onody    
    Stephen K. Onody   
    Chief Executive Officer   
 

 

 

Exhibit Index
     
Exhibit    
Number   Description
99.1
  Press release, dated May 15, 2006, entitled “Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.”